22 April 2018

TIKOMED IS INTERVIEWED AT BIOSPRING ABOUT IBSOLVMIR FOR IMPROVED CELL-THERAPIES BY MIKE WARD

TikoMeds promising Phase 2 project for more efficient cell-therapies was presented at BioEurope Spring in Amsterdam. Below follows an interview by Mike Ward of Adam Bruce, Founder and CEO of TikoMed.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

4 March 2019
TFS International AB (TFS) appointed CRO representative for TIKOMED’s phase 2 study in clinical islet transplantation
Viken – 4th March 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
8 February 2019
TIKOMED successfully closed fundraising of 8 Million Euros
Viken – 8th February 2019 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced its…
Read More
6 February 2019
Shadow Lake Group appointed Strategic Advisor and Business Development representative for the licensing process of IBsolvMIR® in Canada
Viken – 6th February 2019 – TIKOMED, a Swedish privately held biopharmaceutical company today announced…
Read More
SEE MORE